Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study

Conclusions: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.PMID:34645648 | DOI:10.1158/1078-0432.CCR-21-0158

Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Setsuko K Chambers Erika P Hamilton Lee-May Chen Amit M Oza Sharad A Ghamande Gottfried E Konecny Steven C Plaxe Daniel L Spitz Jill J J Geenen Tiffany A Troso-Sandoval Janiel M Cragun Esteban Rodrigo Imedio Sanjeev Kumar Ganesh M Mugundu Source Type: research